Sandoz has launched a generic version of United Therapeutics’ Remodulin (treprostinil) injectable with 180-day exclusivity in the US.
The Novartis subsidiary said it would collaborate with RareGen to market the generic treprostinil injectable, which is available in four strengths – 1mg/ml, 2
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?